ArticleScientific reports2026
Design, synthesis, and antitumor evaluation of new functionalized spiroindenopyridotriazinepyrans.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is the second leading cause of death worldwide. Main problem in current cancer therapy strategies is resistance to anti-cancer drugs and side effects. Therefore, the design of new compounds with high anticancer activity and low toxicity toward normal cells is highly desirable. In the present study, we focused on the development of novel spiropyran derivatives. A practical one-pot synthetic method was developed for preparation of spiroindenopyridotriazinepyrans containing pyranopyridine, and triazine constituent units within a unified molecular framework. This method employs readily accessible starting materials, proceeds under mild conditions, and affords products that can be purified without chromatographic techniques. The structures of the products were confirmed by NMR, IR, and mass spectrometry. Moreover, we explored the anticancer effects of related products against human pancreatic cancer cells (Panc1), human breast cancer cells (MDA-MB-231) and normal cells HDF (human dermal fibroblast) by using MTT assay and DAPI staining. Our results revealed that 9d, 9e, and 9f compounds have the highest cytotoxic activity on different cancer cells. It seems that these synthetic compounds may be a promising candidate to design therapeutic agents against different cancers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.